Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jul 15, 2022 6:44pm

155 Views

Post# 34828266

RE:I would like to do lunch with...

haha you would fit in perfectly with those guys, glad you brought up oldfart's name another one of your buddies that thought he was smarter than everyone else i remeber him saying about 4 months ago calling the bottom on hexo and he said he was averaging down and loaded up @$1.17. i know is avg is a lot higher maybe $6 or $7 on a 25cent stock, and then there is quinntard with his $10 avg. so tell us davgro how are you making out with hexo and all your us mso stocks we all know they are in the tank.
mugsy is not going to like you anymore for posting that canaccord price target. lol

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide